The Green Supply Chain Corporate Information Transparency Index (CITI) evaluates consumer-facing companies that have a sizeable supply chain in China. The evaluation uses government supervision data and public information to assess the environmental management of their supply chains in China. This company received a score of 10.34/100 (retrieved 24 Nov 2023).

This company's ownership structure is complex, but it is at least 24.8% owned by Shanghai SASAC, which is owned by the Govt of China, which has received criticisms, particularly over human rights.

In 2016 China's anti-monopoly regulator fined five domestic drug firms, including a subsidiary of this company, a total of close to 4 million yuan ($607,977) for fixing the prices of their medicines. Between April 2014 to September 2015 the companies raised the price of allopurinol tablets, a drug used to treat gout and kidney disease, the National Development and Reform Commission (NDRC) said in statements on its website.

This company received an S&P Global ESG Score of 20/100 in the Health Care Providers & Services category of the S&P Global Corporate Sustainability Assessment, an annual evaluation of companies' sustainability practices (last updated 23 Sep 2022). The rankings are based on an analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, environmental reporting, climate strategy, human rights and labour practices.